Mylan executives will not testify at a Nov. 30 Senate judiciary committee hearing over the EpiPen, citing the U.S. Justice Department’s refusal to testify.
“Mylan respectfully declines the invitation to testify,” Mylan’s lawyers, Latham & Watkins, said in a letter dated Friday and released Monday by committee chairman Sen. Chuck Grassley.
Mr. Grassley, R-Iowa, had called the hearing to examine the proposed $465 million settlement with the Justice Department for overcharging Medicaid for the EpiPen emergency allergy shot. The senator and others have criticized the deal as too soft on Mylan.
This month, the Justice Department said it would not attend the hearing, saying it could not comment on pending matters.
“The Obama administration is dodging accountability for an expensive problem and now a company is following its bad example,” Mr. Grassley said in a statement. “One way or another, I intend to get answers for patients and taxpayers.”
The committee is considering rescheduling the hearing, possibly with witness subpoenas, Jill Gerber, Mr. Grassley’s spokeswoman, said in an email.
Read More
For years, EpiPen was misclassified as a generic instead of a brand-name drug, and Mylan paid a lower rebate to Medicaid, which led to states being overcharged. Companies are responsible for ensuring drugs are correctly classified. Mylan has denied any wrongdoing.
Mr. Grassley said he has asked the Securities and Exchange Commission if it is investigating whether Mylan misled investors by announcing the proposed settlement.
“It has now been over five weeks since Mylan’s press release and apparently a settlement has still not been executed,” Mr. Grassley wrote to SEC chair Mary Jo White on Nov. 15.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.
Here is a copy of Mylan’s letter:





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.